The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 107, Issue 6, 2009, Pages 826-836

  Nikitakis, Nikolaos G ^a   Scheper, Mark A ^b,c   Papanikolaou, Vasileios S ^d   Sauk, John J ^e  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d University of Louisville ^*  (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; STAT3 PROTEIN; SULINDAC;

ADENOCARCINOMA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; SALIVARY GLAND TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; RNA, MESSENGER; SALIVARY GLAND NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SULINDAC;

EID: 67349172533     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2008.12.054     Document Type: Article

References (65)

1. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 98 (1999) 295-303
2. Buettner R., Mora L.B., and Jove R. Activated Stat signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8 (2002) 945-954
3. Kijima T., Niwa H., Steinman R.A., Drenning S.D., Gooding W.E., Wentzel A.L., et al. Stat3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 13 (2002) 355-362
4. Grandis J.R., Drenning S.D., Zeng Q., Watkins S.C., Melhem M.F., Endo S., et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97 (2000) 4227-4232
5. Nikitakis N.G., Siavash H., and Sauk J.J. Targeting the Stat pathway in head and neck cancer: recent advances and future prospects. Curr Cancer Drug Targets 4 (2004) 637-651
6. Bowman T., Garcia R., Turkson J., and Jove R. Stats in oncogenesis. Oncogene 19 (2000) 2474-2488
7. Bromberg J.F. Activation of Stat proteins and growth control. Bioessays 23 (2001) 161-169
8. Grandis J.R., Zeng Q., and Drenning S.D. Epidermal growth factor receptor-mediated Stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope 110 (2000) 868-874
9. Xi S., Zhang Q., Dyer K.F., Lerner E.C., Smithgall T.E., Gooding W.E., et al. Src kinases mediate Stat growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 278 (2003) 31574-31583
10. Sriuranpong V., Park J.I., Amornphimoltham P., Patel V., Nelkin B.D., and Gutkind J.S. Epidermal growth factor receptor-independent constitutive activation of Stat3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63 (2003) 2948-2956
11. Siavash H., Nikitakis N.G., and Sauk J.J. Abrogation of IL-6-mediated JAK signalling by the cyclopentenone prostaglandin 15d-PGJ(2) in oral squamous carcinoma cells. Br J Cancer 91 (2004) 1074-1080
12. Neville B.W., Damm D.D., Allen C.M., and Bouquot J.E. Oral and maxillofacial pathology. In: Neville B.W., Damm D.D., Allen C.M., and Bouquot J.E. (Eds). Salivary gland pathology. 2nd (2002), Saunders, Philadelphia p. 406-30
13. Agulnik M., and Siu L.L. An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents. Curr Med Chem Anticancer Agents 4 (2004) 543-551
14. Stenman G. Fusion oncogenes and tumor type specificity-insights from salivary gland tumors. Semin Cancer Biol 15 (2005) 224-235
15. Licitra L., Locati L.D., Bossi P., and Cantu G. Head and neck tumors other than squamous cell carcinoma. Curr Opin Oncol 16 (2004) 236-241
16. Pramoonjago P., Baras A.S., and Moskaluk C.A. Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. Oncogene 25 (2006) 5626-5639
17. Li J., El-Naggar A., and Mao L. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 104 (2005) 771-776
18. Kaye F.J. Emerging biology of malignant salivary gland tumors offers new insights into the classification and treatment of mucoepidermoid cancer. Clin Cancer Res 12 (2006) 3878-3881
19. Piechocki M.P., Yoo G.H., Dibbley S.K., Amjad E.H., and Lonardo F. Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int J Cancer 119 (2006) 441-454
20. Wen X., Lin H.H., Shih H.M., Kung H.J., and Ann D.K. Kinase activation of the nonreceptor tyrosine kinase Etk/BMX alone is sufficient to transactivate Stat-mediated gene expression in salivary and lung epithelial cells. J Biol Chem 274 (1999) 38204-38210
21. de Araújo V.C., Furuse C., Cury P.R., Altemani A., and de Araújo N.S. Stat3 expression in salivary gland tumours. Oral Oncol 44 (2008) 439-445
22. Vered M., Braunstein E., and Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24 (2002) 632-636
23. Fan C.Y., Melhem M.F., Hosal A.S., Grandis J.R., and Barnes E.L. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 127 (2001) 1075-1079
24. Bu R., Purushotham K.R., Kerr M., Tao Z., Jonsson R., Olofsson J., et al. Alterations in the level of phosphotyrosine signal transduction constituents in human parotid tumors. Proc Soc Exp Biol Med 211 (1996) 257-264
25. Gibbons M.D., Manne U., Carroll W.R., Peters G.E., Weiss H.L., and Grizzle W.E. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 111 (2001) 1373-1378
26. Sato N., Kyakumoto S., Sawano K., and Ota M. Proliferative signal transduction by epidermal growth factor (EGF) in the human salivary gland adenocarcinoma (HSG) cell line. Biochem Mol Biol Int 38 (1996) 597-606
27. Kyakumoto S., Kurokawa R., Hoshino M., and Ota M. Co-expression of epidermal growth factor-receptor and c-erb B-2 proto-oncogene product in human salivary-gland adenocarcinoma cell line HSG and the implications for HSG cell autocrine growth. Arch Oral Biol 39 (1994) 569-580
28. Aladib W., Yoshida H., and Sato M. Effect of epidermal growth factor on the cellular proliferation and phenotype of a neoplastic human salivary intercalated duct cell line or its derivatives. Cancer Res 50 (1990) 7650-7661
29. Li F. Survivin study: what is the next wave?. J Cell Physiol 197 (2003) 8-29
30. Kanda N., Seno H., Konda Y., Marusawa H., Kanai M., Nakajima T., et al. Stat3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23 (2004) 4921-4929
31. Aoki Y., Feldman G.M., and Tosato G. Inhibition of Stat3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101 (2003) 1535-1542
32. Lo Muzio L., Pannone G., Staibano S., Mignogna M.D., Rubini C., Mariggio M.A., et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer 89 (2003) 2244-2248
33. Scheper M.A., Sauk J.J., and Nikitakis N.G. COX-independent antineoplastic effects of sulindac in oral cancer are mediated by survivin downregulation. Anticancer Res 26 (2006) 4103-4113
34. Scheper M.A., Nikitakis N.G., and Sauk J.J. Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer. Int J Oral Maxillofac Surg 36 (2007) 632-639
35. Scheper M.A., Nikitakis N.G., Chaisuparat R., Montaner S., and Sauk J.J. Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia 9 (2007) 192-199
36. Nikitakis N.G., Hamburger A.W., and Sauk J.J. The nonsteroidal antiinflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Res 62 (2002) 1004-1007
37. Thompson H.J., Jiang C., Lu J., Mehta R.G., Piazza G.A., Paranka N.S., et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 57 (1997) 267-271
38. Shiff S.J., Qiao L., Tsai L.L., and Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96 (1995) 491-503
39. Piazza G.A., Rahm A.L., Krutzsch M., Sperl G., Paranka N.S., Gross P.H., et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55 (1995) 3110-3116
40. Han E.K., Arber N., Yamamoto H., Lim J.T., Delohery T., Pamukcu R., et al. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 48 (1998) 195-203
41. Lim J.T., Piazza G.A., Han E.K., Delohery T.M., Li H., Finn T.S., et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 58 (1999) 1097-1107
42. Molina M.A., Sitja-Arnau M., Lemoine M.G., Frazier M.L., and Sinicrope F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal antiinflammatory drugs. Cancer Res 59 (1999) 4356-4362
43. Rahman M.A., Dhar D.K., Masunaga R., Yamanoi A., Kohno H., and Nagasue N. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 60 (2000) 2085-2089
44. Nikitakis N.G., Hebert C., Lopes M.A., Reynolds M.A., and Sauk J.J. PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer 98 (2002) 817-823
45. Ambrosini G., Adida C., and Altieri D.C. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
46. Chiou S.K., Jones M.K., and Tarnawski A.J. Survivin- an antiapoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 9 (2003) 43-47
47. Weinman E.C., Roche P.C., Kasperbauer J.L., Cha S.S., Sargent D.J., Cheville J., et al. Characterization of antigen processing machinery and survivin expression in tonsillar squamous cell carcinoma. Cancer 97 (2003) 2203-2211
48. Jaskoll T., Chen H., Min Zhou Y., Wu D., and Melnick M. Developmental expression of survivin during embryonic submandibular salivary gland development. BMC Dev Biol 1 (2001) 5
49. Szlávik V., Vág J., Markó K., Demeter K., Madarász E., Oláh I., Zelles T., O'Connell B.C., and Varga G. Matrigel-induced acinar differentiation is followed by apoptosis in HSG cells. J Cell Biochem 103 (2008) 284-295
50. Sturmer T., Buring J.E., Lee I.M., Kurth T., Gaziano J.M., and Glynn R.J. Colorectal cancer after start of nonsteroidal antiinflammatory drug use. Am J Med 119 (2006) 494-502
51. Krysan K., Reckamp K.L., Sharma S., and Dubinett S.M. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 6 (2006) 209-220
52. Dai Y., and Wang W.H. Non-steroidal antiinflammatory drugs in prevention of gastric cancer. World J Gastroenterol 12 (2006) 2884-2889
53. Mohan S., and Epstein J.B. Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol 39 (2003) 537-546
54. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24 (2003) 96-102
55. Elder D.J., Halton D.E., Hague A., and Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 3 (1997) 1679-1683
56. Grosch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98 (2006) 736-747
57. Loy A.H., Putti T.C., and Tan L.K. Cyclooxygenase-2 expression in Warthin's tumour. J Laryngol Otol 119 (2005) 515-518
58. Aoki T., Tsukinoki K., Karakida K., Ota Y., Otsuru M., and Kaneko A. Expression of cyclooxygenase-2, Bcl-2 and Ki-67 in pleomorphic adenoma with special reference to tumor proliferation and apoptosis. Oral Oncol 40 (2004) 954-959
59. Aoki T., Tsukinoki K., Kurabayashi H., Sasaki M., Yasuda M., Ota Y., et al. Hepatocyte growth factor expression correlates with cyclooxygenase-2 pathway in human salivary gland tumors. Oral Oncol 42 (2006) 51-56
60. Sakurai K., Urade M., Noguchi K., Kishimoto H., Ishibashi M., Yasoshima H., et al. Increased expression of cyclooxygenase-2 in human salivary gland tumors. Pathol Int 51 (2001) 762-769
61. Sakamoto T., Uozaki H., Kondo K., Imauchi Y., Yamasoba T., Sugasawa M., et al. Cyclooxygenase-2 regulates the degree of apoptosis by modulating Bcl-2 protein in pleomorphic adenoma and mucoepidermoid carcinoma of the parotid gland. Acta Otolaryngol 125 (2005) 191-195
62. Zhang T., Fields J.Z., Ehrlich S.M., and Boman B.M. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J Pharmacol Exp Ther 308 (2004) 434-437
63. Teh S.H., Hill A.K., Foley D.A., McDermott E.W., O'Higgins N.J., and Young L.S. COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells. J Cell Biochem 91 (2004) 796-807
64. Krysan K., Merchant F.H., Zhu L., Dohadwala M., Luo J., Lin Y., et al. COX-2-dependent stabilization of survivin in nonsmall cell lung cancer. FASEB J 18 (2004) 206-208
65. Kobayashi M., Nakamura S., Shibata K., Sahara N., Shigeno K., Shinjo K., et al. Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells. Eur J Haematol 75 (2005) 212-220